Novartis reports topline Phase III results for pelacarsen
Novartis announced topline results from the Phase III Lp(a)HORIZON trial of pelacarsen in patients with elevated lipoprotein(a) and established cardiovascular disease. The supplied headline does not state whether the results were positive or negative.
By DoomRadar · Published on DoomRadar .
Why it matters
The findings could affect future treatment options for a high-risk cardiovascular population.
Related source links
These links were collected with this event. Recorded source dates may reflect when a link was found. Article publication dates are shown only when available from the source. Open the originals for their full context.
- Novartis Pharma AG: Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) ↗finanznachrichten.de · Recorded source date: Sep 4, 2026, 8:48 PM UTC
AI-assisted, source-based analysis. Methodology · Report a correction